Forced Vital Capacity remains the anchor endpoint for pulmonary fibrosis trials and the filed remains split on torn on its value. What’s more the field is evolving to capture a more complete picture of disease progression and therapeutic impact. This panel will dig into FVC and secondary endpoints, the emerging role of quantitative HRCT and other imaging biomarkers, the evidence required for regulatory acceptance, standardization across providers, and the integration of multi-modal endpoints into trial design, all to ensure you leave with a clear understanding of how to design trials that balance traditional FVC measurements with innovative endpoints, enabling robust efficacy assessment, regulatory alignment, and differentiation in an increasingly complex ILD landscape.

• The continued relevance of FVC as a surrogate for disease progression and mortality in IPF and PPF
• How secondary endpoints can complement FVC to reveal meaningful changes in symptoms, quality of life, and disease biology
• Advances in quantitative imaging, including AI-driven HRCT, and the pathway toward regulatory qualification
• Strategies for integrating multi-modal endpoints into trial design without overcomplicating study execution
• Practical considerations for trial sponsors: standardization, subgroup analysis, and managing background therapy